Pathology: mHCC - 1st line (L1);
mHCC - 1st line (L1) | |||||||||||
IMbrave-150, 2020 | COSMIC-312, 2023 | CARES-310, 2023 | EMERALD-1, 2024 | HIMALAYA, 2022 | CheckMate 459, 2019 | CheckMate 9DW, 2024 | LEAP 002, 2023 | ORIENT-32, 2021 | RATIONALE 301, 2024 | ||
durvalumab plus bevacizumab | 1 | T1 | |||||||||
nivolumab plus ipilimumab plus SoC | 1 | T1 | |||||||||
Tislelizumab | 1 | T1 | |||||||||
atezolizumab plus cabozantinib | 1 | T1 | |||||||||
camrelizumab based treatment | 1 | T1 | |||||||||
pembrolizumab plus lenvatinib | 1 | T1 | |||||||||
durvalumab plus tremelimumab | 1 | T1 | |||||||||
sintilimab | 1 | T1 | |||||||||
atezolizumab plus bevacizumab | 1 | T1 | |||||||||
nivolumab alone | 1 | T1 | |||||||||
placebo | 0 | T0 | |||||||||
VEGF(R) inhibitor | 0 | T0 | |||||||||
lenvatinib | 0 | T0 | |||||||||
sorafenib | 0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 |